Drug Utilization Patterns for Oxycodone-Containing Analgesics, 2009-2016

Tracy Pham, Pharm.D.
Drug Utilization Data Analyst
Division of Epidemiology II
Office of Pharmacovigilance and Epidemiology
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

April 5, 2017

Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee
Outline

• Sales distribution
• Outpatient retail utilization
  – Dispensed prescription data
  – Patient data
  – Prescriber specialties
  – Diagnoses data
• Data limitations
• Summary of findings
Oxycodone-Containing Analgesics*  
(including formulations designed to deter abuse)

<table>
<thead>
<tr>
<th>Immediate-Release Formulations (IR)</th>
<th>Extended-Release Formulations (ER)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Single-ingredient oxycodone IR</td>
<td>• Single-ingredient oxycodone ER (OxyContin ER, Xtampza ER, and generic oxycodone ER)</td>
</tr>
<tr>
<td>• <strong>Combination oxycodone-containing IR</strong></td>
<td>• <strong>Combination oxycodone/acetaminophen ER</strong></td>
</tr>
<tr>
<td>o Oxycodone/acetaminophen IR</td>
<td></td>
</tr>
<tr>
<td>o Oxycodone/ibuprofen IR</td>
<td></td>
</tr>
<tr>
<td>o Oxycodone/acetylsalicylic acid IR</td>
<td></td>
</tr>
</tbody>
</table>

*Troxycra ER (oxycodone/naltrexone) and Targiniq (oxycodone/naloxone) were not analyzed because although FDA approved, they were not marketed in the U.S. during the study time period.
Sales Distribution Data

National estimates of bottles of oxycodone-containing analgesics sold from manufacturers to retail and non-retail channels of distribution in U.S.

<table>
<thead>
<tr>
<th></th>
<th>Retail</th>
<th>Mail-Order/Specialty</th>
<th>Non-Retail</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxycodone-containing analgesics</td>
<td>67%</td>
<td>&lt;1%</td>
<td>32%</td>
</tr>
</tbody>
</table>

Prescription Utilization Database

• QuintilesIMS, National Prescription Audit™ Database

• Measures prescriptions dispensed from outpatient retail pharmacies to patients

• Data are projected to provide national estimates of utilization
Oxycodone Prescription Data

National estimates of prescriptions dispensed for oxycodone-containing analgesics from U.S. outpatient retail pharmacies

Patient Utilization Database

• QuintilesIMS, Total Patient Tracker™ Database

• Number of unique patients who received prescriptions dispensed from outpatient retail pharmacies

• Data are projected to provide national estimates of utilization
Oxycodone Patient Data

National estimates of patients who were dispensed prescriptions for oxycodone-containing analgesics from U.S. outpatient retail pharmacies

Top Five Prescriber Specialties

National estimates of outpatient retail prescriptions dispensed for single-ingredient oxycodone IR analgesics by top five prescriber specialties in 2016

U.S. Office-Based Physician Survey Data

• inVentiv Health TreatmentAnswers™ and TreatmentAnswers™ with Pain Panel

• Monthly survey of 3,200 office-based physicians

• Data are nationally projected to reflect national prescribing patterns

• Data provide insight into prescriber intent
Diagnoses Data

Top groups of diagnoses (ICD-10) associated with the mentions of single-ingredient oxycodone IR analgesics as reported by office-based physician surveys in 2016

Limitations

• No linkage between a dispensed prescription and a diagnosis
• No medical charts available for validation
• Dispensing trends may not apply to non-retail or mail-order/specialty settings
• Office-based physician survey data may not capture diagnosis data from subspecialty prescribers in inpatient or clinic settings, such as oncology clinics
  – A diagnosis mention does not necessarily result in a prescription being generated
Single-Ingredient Oxycodone IR products:

• Outpatient retail utilization increased from 2.4 million patients in 2009 to 5.9 million patients in 2016

• The top prescribers were primary care physicians, followed by mid-level practitioners

• The top group of diagnoses were conditions related to the diseases of the musculoskeletal system and connective tissue
Thank you